| 251 |
17300592 | Vildagliptin in combination with pioglitazone improves glycaemic control in patients with type 2 diabetes failing thiazolidinedione monotherapy: a randomized, placebo-controlled study. | 2007 Mar |
1 |
| 252 |
17353295 | beta-cell failure in diabetes and preservation by clinical treatment. | 2007 Apr |
1 |
| 253 |
17379930 | Incretins: a new treatment option for type 2 diabetes? | 2007 Feb |
1 |
| 254 |
17387446 | Addition of vildagliptin to insulin improves glycaemic control in type 2 diabetes. | 2007 Jun |
1 |
| 255 |
17456545 | The role of vildagliptin in the management of type 2 diabetes mellitus. | 2007 May |
4 |
| 256 |
17486328 | The influence of hepatic impairment on the pharmacokinetics of the dipeptidyl peptidase IV (DPP-4) inhibitor vildagliptin. | 2007 Jul |
4 |
| 257 |
17519080 | Effect of the novel oral dipeptidyl peptidase IV inhibitor vildagliptin on the pharmacokinetics and pharmacodynamics of warfarin in healthy subjects. | 2007 May |
3 |
| 258 |
17559747 | A review of the effects of antihyperglycaemic agents on body weight: the potential of incretin targeted therapies. | 2007 Jul |
2 |
| 259 |
17563048 | Vildagliptin: a novel oral therapy for type 2 diabetes mellitus. | 2007 Jun |
4 |
| 260 |
17593275 | Antihyperglycaemic therapy in elderly patients with type 2 diabetes: potential role of incretin mimetics and DPP-4 inhibitors. | 2007 Aug |
1 |
| 261 |
17593276 | Dipeptidyl peptidase 4 inhibition and vildagliptin therapy for type 2 diabetes. | 2007 Aug |
2 |
| 262 |
17596103 | Pharmacokinetics and pharmacodynamics of vildagliptin in patients with type 2 diabetes mellitus. | 2007 |
4 |
| 263 |
17656620 | Dose proportionality and the effect of food on vildagliptin, a novel dipeptidyl peptidase IV inhibitor, in healthy volunteers. | 2007 Sep |
2 |
| 264 |
17660482 | Evaluation of pharmacokinetic interactions between vildagliptin and digoxin in healthy volunteers. | 2007 Aug |
1 |
| 265 |
17698900 | The dipeptidyl peptidase 4 inhibitor vildagliptin does not accentuate glibenclamide-induced hypoglycemia but reduces glucose-induced glucagon-like peptide 1 and gastric inhibitory polypeptide secretion. | 2007 Nov |
2 |
| 266 |
17713976 | The absolute oral bioavailability and population-based pharmacokinetic modelling of a novel dipeptidylpeptidase-IV inhibitor, vildagliptin, in healthy volunteers. | 2007 |
2 |
| 267 |
17848846 | Dipeptidyl peptidase 4 (DPP-4) inhibitors and their role in Type 2 diabetes management. | 2007 Jul-Aug |
1 |
| 268 |
17877545 | The DPP-4 inhibitor vildagliptin: robust glycaemic control in type 2 diabetes and beyond. | 2007 Sep |
4 |
| 269 |
17931461 | Evaluation of the potential for steady-state pharmacokinetic interaction between vildagliptin and simvastatin in healthy subjects. | 2007 Dec |
2 |
| 270 |
17992639 | Improved meal-related insulin processing contributes to the enhancement of B-cell function by the DPP-4 inhibitor vildagliptin in patients with type 2 diabetes. | 2007 Nov |
2 |
| 271 |
18632049 | New treatments for type 2 diabetes--the DPP4 inhibitors. | 2007 Dec |
1 |
| 272 |
30736119 | DPP-4 inhibitors as a new target of action for Type 2 diabetes mellitus: a focus on vildagliptin. | 2007 Sep |
2 |
| 273 |
16548792 | Vildagliptin: an inhibitor of dipeptidyl peptidase-4 with antidiabetic properties. | 2006 Apr |
2 |
| 274 |
16682937 | Therapies for the treatment of type 2 diabetes mellitus based on incretin action. | 2006 Jun |
2 |
| 275 |
16816950 | Vildagliptin therapy reduces postprandial intestinal triglyceride-rich lipoprotein particles in patients with type 2 diabetes. | 2006 Sep |
1 |
| 276 |
16823726 | Twelve-week monotherapy with the DPP-4 inhibitor vildagliptin improves glycemic control in subjects with type 2 diabetes. | 2006 Jun |
2 |
| 277 |
16969429 | Vildagliptin: a novel DPP-4 inhibitor with pancreatic islet enhancement activity for treatment of patients with type 2 diabetes. | 2006 Aug |
2 |
| 278 |
17098089 | The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes. | 2006 Nov 11 |
1 |
| 279 |
17100408 | Vildagliptin. | 2006 |
2 |
| 280 |
15886245 | Vildagliptin, a dipeptidyl peptidase-IV inhibitor, improves model-assessed beta-cell function in patients with type 2 diabetes. | 2005 Aug |
2 |
| 281 |
15907807 | Inhibition of dipeptidyl-peptidase IV catalyzed peptide truncation by Vildagliptin ((2S)-{[(3-hydroxyadamantan-1-yl)amino]acetyl}-pyrrolidine-2-carbonitrile). | 2005 Jul 1 |
2 |
| 282 |
16043735 | Improved meal-related beta-cell function and insulin sensitivity by the dipeptidyl peptidase-IV inhibitor vildagliptin in metformin-treated patients with type 2 diabetes over 1 year. | 2005 Aug |
2 |
| 283 |
16219012 | Improved glycaemic control with dipeptidyl peptidase-4 inhibition in patients with type 2 diabetes: vildagliptin (LAF237) dose response. | 2005 Nov |
2 |
| 284 |
16318402 | Glucagon-like peptide-1-based therapies for the treatment of type 2 diabetes mellitus. | 2005 |
1 |
| 285 |
17491680 | New therapeutic strategies for the treatment of type 2 diabetes mellitus based on incretins. | 2005 Summer |
1 |